Last reviewed · How we verify

Dexmedetomidine-Dexamethasone

University of Chile · FDA-approved active Small molecule

This combination drug pairs dexmedetomidine (an alpha-2 adrenergic agonist) with dexamethasone (a corticosteroid) to provide sedation and anti-inflammatory effects.

This combination drug pairs dexmedetomidine (an alpha-2 adrenergic agonist) with dexamethasone (a corticosteroid) to provide sedation and anti-inflammatory effects. Used for Sedation and analgesia in perioperative or intensive care settings, Reduction of postoperative inflammation and pain.

At a glance

Generic nameDexmedetomidine-Dexamethasone
SponsorUniversity of Chile
Drug classAlpha-2 adrenergic agonist / Corticosteroid combination
TargetAlpha-2 adrenergic receptor; Glucocorticoid receptor
ModalitySmall molecule
Therapeutic areaAnesthesia / Critical Care / Perioperative Medicine
PhaseFDA-approved

Mechanism of action

Dexmedetomidine acts as a selective alpha-2 adrenergic agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic alpha-2 receptors in the central nervous system. Dexamethasone is a potent glucocorticoid that suppresses inflammation and immune responses. The combination leverages both sedative-analgesic and anti-inflammatory properties for perioperative or critical care use.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: